Biggest changeAdditionally, we recognized a $7.5 million non-cash impairment charge for two related private company investments that is included within Other income (expense) in the consolidated statement of operations. 22 Net Income and Diluted Net Income Per Share Reconciliation GAAP to Non-GAAP Reconciliation Fiscal Year Ended September 28, 2024 September 30, 2023 (in thousands, except per share amount) GAAP net income attributable to Central Garden & Pet Company $ 107,983 $ 125,643 Facility closures (1)(2)(3)(5) 27,842 15,672 Intangible impairments (6)(7) 12,790 6,731 Litigation settlement (8) (3,200) — Independent channel distribution business sale (4) — (5,844) Investment impairment (8) 7,461 — Tax effect of adjustments (10,437) (3,705) Non-GAAP net income attributable to Central Garden & Pet Company $ 142,439 $ 138,497 GAAP diluted net income per share $ 1.62 $ 1.88 Non-GAAP diluted net income per share $ 2.13 $ 2.07 Shares used in GAAP and non-GAAP diluted net income per share calculation 66,860 66,783 Operating Income Reconciliation GAAP to Non-GAAP Reconciliation Fiscal Year Ended September 28, 2024 Fiscal Year Ended September 30, 2023 GAAP Adjustments (1)(2)(3)(6)(8) Non-GAAP GAAP Adjustments (4)(5)(7) Non-GAAP (in thousands) (in thousands) Net sales $ 3,200,460 $ — $ 3,200,460 $ 3,310,083 $ — $ 3,310,083 Cost of goods sold and occupancy 2,256,725 16,349 2,240,376 2,363,241 9,761 $ 2,353,480 Gross profit 943,735 (16,349) 960,084 946,842 (9,761) $ 956,603 Selling, general and administrative expenses 758,348 21,083 737,265 736,196 6,798 $ 729,398 Income from operations $ 185,387 $ (37,432) $ 222,819 $ 210,646 $ (16,559) $ 227,205 Gross margin 29.5 % 30.0% 28.6% 28.9 % Operating margin 5.8 % 7.0% 6.4% 6.9 % Pet Segment Operating Income Reconciliation GAAP to Non-GAAP Reconciliation Fiscal Year Ended September 28, 2024 September 30, 2023 (in thousands) GAAP operating income $ 203,425 $ 198,004 Facility closures (1)(5) 7,549 15,672 Intangible impairments (6)(7) 12,790 2,785 Non-GAAP operating income $ 223,764 $ 216,461 GAAP operating margin 11.1 % 10.5 % Non-GAAP operating margin 12.2 % 11.5 % 23 Garden Segment Operating Income Reconciliation GAAP to Non-GAAP Reconciliation Fiscal Year Ended September 28, 2024 September 30, 2023 (in thousands) GAAP operating income $ 81,893 $ 123,455 Facility closures (1)(2)(3) 20,293 — Independent channel distribution business sale (4) — (5,844) Intangible impairments (7) — 3,946 Non-GAAP operating income $ 102,186 $ 121,557 GAAP operating margin 6.0 % 8.6 % Non-GAAP operating margin 7.5 % 8.5 % Organic Net Sales Reconciliation GAAP to Non-GAAP Reconciliation Fiscal Year Ended September 28, 2024 Net sales (GAAP) Effect of acquisitions & divestitures on net sales Net sales organic (in millions) Reported net sales FY 2024 $ 3,200.5 $ 66.4 $ 3,134.1 Reported net sales FY 2023 3,310.1 48.1 3,262.0 $ decrease $ (109.6) $ 18.3 $ (127.9) % decrease (3.3) % (3.9) % Organic Pet Segment Net Sales Reconciliation GAAP to Non-GAAP Reconciliation Fiscal Year Ended September 28, 2024 Net sales (GAAP) Effect of acquisitions & divestitures on net sales Net sales organic (in millions) Reported net sales FY 2024 $ 1,832.8 $ 66.4 $ 1,766.4 Reported net sales FY 2023 1,877.2 — 1,877.2 $ decrease $ (44.4) $ 66.4 $ (110.8) % decrease (2.4) % (5.9) % Organic Garden Segment Net Sales Reconciliation GAAP to Non-GAAP Reconciliation Fiscal Year Ended September 28, 2024 Net sales (GAAP) Effect of acquisitions & divestitures on net sales Net sales organic (in millions) Reported net sales FY 2024 $ 1,367.7 $ — $ 1,367.7 Reported net sales FY 2023 1,432.9 48.1 1,384.8 $ decrease $ (65.2) $ (48.1) $ (17.1) % decrease (4.6) % (1.2) % 24 Adjusted EBITDA Reconciliation GAAP to Non-GAAP Reconciliation Fiscal Year Ended September 28, 2024 Pet Garden Corp Total (in thousands) Net income attributable to Central Garden & Pet $ — $ — $ — $ 107,983 Interest expense, net — — — 37,872 Other expense — — — 5,090 Income tax expense — — — 33,112 Net income attributable to noncontrolling interest — — — 1,330 Sum of items below operating income — — — 77,404 Income (loss) from operations 203,425 81,893 (99,931) 185,387 Depreciation & amortization 43,642 44,403 2,762 90,807 Noncash stock-based compensation — — 20,583 20,583 Non-GAAP adjustments (1)(2)(3)(6)(8) 20,339 20,293 (3,200) 37,432 Adjusted EBITDA $ 267,406 $ 146,589 $ (79,786) $ 334,209 Adjusted EBITDA Reconciliation GAAP to Non-GAAP Reconciliation Fiscal Year Ended September 30, 2023 Pet Garden Corp Total (in thousands) Net income attributable to Central Garden & Pet $ — $ — $ — $ 125,643 Interest expense, net — — — 49,663 Other income — — — (1,462) Income tax expense — — — 36,348 Net income attributable to noncontrolling interest — — — 454 Sum of items below operating income — — — 85,003 Income (loss) from operations 198,004 123,455 (110,813) 210,646 Depreciation & amortization 41,126 43,375 3,199 87,700 Noncash stock-based compensation — — 27,990 27,990 Non-GAAP adjustments (4)(5)(7) 18,457 (1,898) — 16,559 Adjusted EBITDA $ 257,587 $ 164,932 $ (79,624) $ 342,895 Inflation Our revenues and margins are dependent on various economic factors, including rates of inflation, energy costs, interest rates, consumer attitudes toward discretionary spending, currency fluctuations, and other macro-economic factors which may impact levels of consumer spending.
Biggest changeAdditionally, we recognized a $7.5 million non-cash impairment charge for two related private company investments that is included within Other income (expense) in the consolidated statement of operations. 21 Net Income and Diluted Net Income Per Share GAAP to Non-GAAP Reconciliation Fiscal Year Ended September 27, 2025 September 28, 2024 (in thousands, except per share amount) GAAP net income attributable to Central Garden & Pet Company $ 162,843 $ 107,983 Facility closures & business exits (1)(2)(3)(4) 15,005 27,842 Intangible impairments (5) — 12,790 Litigation settlement (6) — (3,200) Investment impairment (6) — 7,461 Tax effect of adjustments (3,654) (10,437) Non-GAAP net income attributable to Central Garden & Pet Company $ 174,194 $ 142,439 GAAP diluted net income per share $ 2.55 $ 1.62 Non-GAAP diluted net income per share $ 2.73 $ 2.13 Shares used in GAAP and non-GAAP diluted net income per share calculation 63,815 66,860 Operating Income GAAP to Non-GAAP Reconciliation Fiscal Year Ended September 27, 2025 Fiscal Year Ended September 28, 2024 GAAP Adjustments (1)(2) Non-GAAP GAAP Adjustments (3)(4)(5)(6) Non-GAAP (in thousands) (in thousands) Net sales $ 3,129,064 $ — $ 3,129,064 $ 3,200,460 $ — $ 3,200,460 Cost of goods sold and occupancy 2,131,728 5,582 2,126,146 2,256,725 16,349 $ 2,240,376 Gross profit $ 997,336 $ (5,582) $ 1,002,918 $ 943,735 $ (16,349) $ 960,084 Selling, general and administrative expenses 747,294 9,423 737,871 758,348 21,083 737,265 Income from operations $ 250,042 $ (15,005) $ 265,047 $ 185,387 $ (37,432) $ 222,819 Gross margin 31.9 % 32.1% 29.5% 30.0% Operating margin 8.0 % 8.5% 5.8% 7.0% Pet Segment Operating Income GAAP to Non-GAAP Reconciliation Fiscal Year Ended September 27, 2025 September 28, 2024 (in thousands) GAAP operating income $ 215,688 $ 203,425 Facility closures (2)(4) 10,018 7,549 Intangible impairments (5) — 12,790 Non-GAAP operating income $ 225,706 $ 223,764 GAAP operating margin 12.0% 11.1% Non-GAAP operating margin 12.5% 12.2% 22 Garden Segment Operating Income GAAP to Non-GAAP Reconciliation Fiscal Year Ended September 27, 2025 September 28, 2024 (in thousands) GAAP operating income $ 142,402 $ 81,893 Facility closures (1)(3) 4,987 20,293 Non-GAAP operating income $ 147,389 $ 102,186 GAAP operating margin 10.7% 6.0% Non-GAAP operating margin 11.1% 7.5% 23 Adjusted EBITDA GAAP to Non-GAAP Reconciliation Fiscal Year Ended September 27, 2025 Pet Garden Corp Total (in thousands) Net income attributable to Central Garden & Pet $ — $ — $ — $ 162,843 Interest expense, net — — — 32,812 Other expense — — — 480 Income tax expense — — — 52,787 Net income attributable to noncontrolling interest — — — 1,120 Income (loss) from operations 215,688 142,402 (108,048) 250,042 Depreciation & amortization 39,916 42,301 2,677 84,894 Noncash stock-based compensation — — 21,060 21,060 Non-GAAP adjustments (1)(2) 10,018 4,987 — 15,005 Adjusted EBITDA $ 265,622 $ 189,690 $ (84,311) $ 371,001 Adjusted EBITDA GAAP to Non-GAAP Reconciliation Fiscal Year Ended September 28, 2024 Pet Garden Corp Total (in thousands) Net income attributable to Central Garden & Pet $ — $ — $ — $ 107,983 Interest expense, net — — — 37,872 Other expense — — — 5,090 Income tax expense — — — 33,112 Net income attributable to noncontrolling interest — — — 1,330 Income (loss) from operations 203,425 81,893 (99,931) 185,387 Depreciation & amortization 43,642 44,403 2,762 90,807 Noncash stock-based compensation — — 20,583 20,583 Non-GAAP adjustments (3)(4)(5)(6) 20,339 20,293 (3,200) 37,432 Adjusted EBITDA $ 267,406 $ 146,589 $ (79,786) $ 334,209 Inflation Our revenues and margins are dependent on various economic factors, including fluctuating rates of inflation on various input costs (e.g., commodities and energy), interest rates, currencies and consumer attitudes toward discretionary spending.
For certain agreements, 30 management estimates are used to develop the quantities and pricing for anticipated purchases, and future purchases could vary significantly from such estimates. (4) Possible performance-based payments associated with prior acquisitions of businesses are not included in the above table, because they are based on future performance of the businesses acquired, which is not yet known.
For certain agreements, management estimates are used to develop the quantities and pricing for anticipated purchases, and future purchases could vary significantly from such estimates. (4) Possible performance-based payments associated with prior acquisitions of businesses are not included in the above table, because they are based on future performance of the businesses acquired, which is not yet known.
We believe these exclusions supplement the GAAP information with a measure that may be useful to investors in assessing the sustainability of our operating performance. 21 • Asset impairment charges : we exclude the impact of asset impairments on intangible assets and investments as such non-cash amounts are inconsistent in amount and frequency.
We believe these exclusions supplement the GAAP information with a measure that may be useful to investors in assessing the sustainability of our operating performance . • Asset impairment charges: we exclude the impact of asset impairments on intangible assets and investments as such non-cash amounts are inconsistent in amount and frequency.
The obligations of each Guarantor under its Guarantee shall be limited to the maximum amount, after giving effect to all other contingent and fixed liabilities of such Guarantor and to any collections from or payments made by or on behalf of any other Guarantor in respect of the obligations of such Guarantor under the guarantee not constituting a fraudulent conveyance or fraudulent transfer under Federal or state law.
The obligations of each Guarantor under its Guarantee shall be limited to the maximum amount, after giving effect to all other contingent and fixed liabilities of such Guarantor and to any collections from or payments made by or on behalf of any other Guarantor in 27 respect of the obligations of such Guarantor under the guarantee not constituting a fraudulent conveyance or fraudulent transfer under Federal or state law.
The qualitative assessment evaluates factors including macro-economic conditions, industry-specific and company-specific considerations, legal and regulatory environments and historical performance. If it is determined that it is more likely than not the fair value of the reporting unit is greater than its carrying amount, it is unnecessary to perform the quantitative goodwill impairment test.
The qualitative assessment 29 evaluates factors including macro-economic conditions, industry-specific and company-specific considerations, legal and regulatory environments and historical performance. If it is determined that it is more likely than not the fair value of the reporting unit is greater than its carrying amount, it is unnecessary to perform the quantitative goodwill impairment test.
Non-GAAP financial measures reflect adjustments based on the following items: • Facility closures and business exit : we have excluded charges related to the closure of distribution and manufacturing facilities and our decision to exit the pottery business as they represent infrequent transactions that impact the comparability between operating periods.
Non-GAAP financial measures reflect adjustments based on the following items: • Facility closures and business exit: we have excluded charges related to the closure of distribution and manufacturing facilities and our decision to exit the pottery business as they represent infrequent transactions that impact the comparability 20 between operating periods.
In connection with our annual goodwill impairment testing performed during fiscal 2024, we made a qualitative evaluation about the likelihood of goodwill impairment to determine whether it was necessary to calculate the fair values of our reporting segments under the goodwill impairment test.
In connection with our annual goodwill impairment testing performed during fiscal year 2024, we made a qualitative evaluation about the likelihood of goodwill impairment to determine whether it was necessary to calculate the fair values of our reporting segments under the goodwill impairment test.
Future net sales and short-term growth rates are estimated for trade names based on management’s forecasted financial results which consider key business drivers such as specific revenue growth initiatives, market share changes and general economic factors such as consumer spending. During fiscal 2024, 2023 and 2022, we performed evaluations of the fair value of our indefinite-lived trade names and trademarks.
Future net sales and short-term growth rates are estimated for trade names based on management’s forecasted financial results which consider key business drivers such as specific revenue growth initiatives, market share changes and general economic factors such as consumer spending. During fiscal 2025, 2024 and 2023, we performed evaluations of the fair value of our indefinite-lived trade names and trademarks.
We completed our qualitative assessment of potential goodwill impairment and determined that it was more likely than not the fair values of our reporting segments were greater than their carrying amount in fiscal year 2022, and accordingly, no further testing of goodwill was required in fiscal year 2022.
We completed our qualitative assessment of potential goodwill impairment and determined that it was more likely than not the fair values of our reporting segments were greater than their carrying amount in fiscal year 2025, and accordingly, no further testing of goodwill was required in fiscal 2025.
Our lawn and garden businesses are highly seasonal with approximately 66% of our Garden segment’s net sales occurring during the second and third fiscal quarters. This seasonality requires the shipment of large quantities of product well ahead of the peak consumer buying periods.
Our lawn and garden businesses are highly seasonal with approximately 64% of our Garden segment’s net sales occurring during the second and third fiscal quarters. This seasonality requires the shipment of large quantities of product well ahead of the peak consumer buying periods.
However, to supplement the financial results prepared in accordance with GAAP, we use non-GAAP financial measures including non-GAAP net income and diluted net income per share, non-GAAP operating income, non-GAAP gross profit and gross margin, non-GAAP selling, general and administrative expense, adjusted EBITDA and organic net sales.
However, to supplement the financial results prepared in accordance with GAAP, we use non-GAAP financial measures including non-GAAP net income and diluted net income per share, non-GAAP operating income, non-GAAP gross profit and gross margin, non-GAAP selling, general and administrative expense and adjusted EBITDA.
We may redeem some or all of the 2030 Notes, at our option at any time on or after October 15, 2025 for 102.063%, on or after October 15, 2026 for 101.375%, on or after October 15, 2027 for 100.688% and on or after October 15, 2028 for 100.0%, plus accrued and unpaid interest.
We may redeem some or all of the 2030 Notes, at our option, in whole or in part, at any time on or after October 15, 2025 for 102.063%, on or after October 15, 2026 for 101.375%, on or after October 15, 2027 for 100.688% and on or after October 15, 2028 for 100.0%, plus accrued and unpaid interest.
We believe the adjustment of this gain supplements the GAAP information with a measure that may be used to assess the performance of our ongoing operations. • Tax impact : adjustment represents the impact of the tax effect of the pre-tax non-GAAP adjustments excluded from non-GAAP net income.
We believe that the exclusion of this gain supplements the GAAP information with a measure that can be used to assess the performance of our ongoing operations. • Tax impact: adjustment represents the impact of the tax effect of the pre-tax non-GAAP adjustments excluded from non-GAAP net income.
In connection with our annual goodwill impairment testing performed during fiscal year 2022, we made a qualitative evaluation about the likelihood of goodwill impairment to determine whether it was necessary to calculate the fair values of our reporting segments under the goodwill impairment test.
In connection with our annual goodwill impairment testing performed during fiscal 2025, we made a qualitative evaluation about the likelihood of goodwill impairment to determine whether it was necessary to calculate the fair values of our reporting segments under the goodwill impairment test.
Adjusted EBITDA is defined by us as income before income tax, net other expense, net interest expense and depreciation and amortization and stock-based compensation expense (or operating income plus depreciation and amortization expense and stock-based compensation expense). Adjusted EBITDA further excludes one-time charges related to facility closures exits of business, intangible and investment impairments and gains from a litigation settlement.
Adjusted EBITDA is defined by us as income before income tax, net other expense, net interest expense, depreciation and amortization and stock-based compensation expense (or operating income plus depreciation and amortization expense and stock-based compensation expense). Adjusted EBITDA further excludes one-time charges related to facility closures, exits of businesses, intangible and investment impairments and gains from litigation.
Intangible Impairments (6) During the fourth quarter of fiscal 2024, we recognized a non-cash impairment charge in our Pet segment of $12.8 million related to the impairment of intangible assets due primarily to changing market conditions resulting from the decline in demand for durable products and increased international competition.
Intangible Impairments (5) During fiscal 2024, we recognized a non-cash impairment charge in our Pet segment of $12.8 million related to the impairment of intangible assets due primarily to changing market conditions resulting from the decline in demand for durable products and increased international competition.
Fiscal 2023 Compared to Fiscal 2022 For a discussion of our results of operations in fiscal 2023 compared to fiscal 2022, please see Item 7 of our Annual Report on Form 10-K for the fiscal year ended September 30, 2023 filed with the SEC. Use of Non-GAAP Financial Measures We report our financial results in accordance with GAAP.
Fiscal 2024 Compared to Fiscal 2023 For a discussion of our results of operations in fiscal 2024 compared to fiscal 2023, please see Item 7 of our Annual Report on Form 10-K for the fiscal year ended September 28, 2024 filed with the SEC. Use of Non-GAAP Financial Measures We report our financial results in accordance with GAAP.
We were in compliance with all financial covenants as of September 28, 2024. 27 $500 million 4.125% Senior Notes due 2030 In October 2020, we issued $500 million aggregate principal amount of 4.125% senior notes due October 2030 (the "2030 Notes").
We were in compliance with all financial covenants as of September 27, 2025. $500 million 4.125% Senior Notes due 2030 In October 2020, we issued $500 million aggregate principal amount of 4.125% senior notes due October 2030 (the "2030 Notes").
The Company may redeem some or all of the 2031 Notes at its option, at any time on or after April 30, 2026 for 102.063%, on or after April 30, 2027 for 101.375%, on or after April 30, 2028 for 100.688% and on or after April 30, 2029 for 100.0%, plus accrued and unpaid interest.
We may redeem some or all of the 2031 Notes at our option, at any time on or after April 30, 2026 for 102.063%, on or after April 30, 2027 for 101.375%, on or after April 30, 2028 for 100.688% and on or after April 30, 2029 for 100.0%, plus accrued and unpaid interest.
Borrowings under the Credit Facility will bear interest at an index based on SOFR (which will not be less than 0.00%) or, at our option, the Base Rate, plus, in either case, an applicable margin based on our usage under the Credit Facility.
Borrowings under the Credit Facility will bear interest at an index based on SOFR (which will not be less than 0.00%) or, at our option, the Base Rate, plus, in either case, an applicable margin based on the average availability level under the Credit Facility.
In fiscal years 2021 through 2023, we were adversely impacted by high input costs due to inflation, particularly relating to prices for grain and seed, fuel and the ingredients used in our garden controls and fertilizer business as well as heightened import costs such as shipping container costs and tariffs.
In fiscal year 2021 through 2023, our operating results were adversely impacted by high input costs due to inflation, particularly relating to prices for grain and seed, fuel and the ingredients used in our garden controls and fertilizer business as well as heightened import costs such as shipping container costs and tariffs.
The holders of the 2031 Notes have the right to require us to repurchase all or a portion of the 2031 Notes at a purchase price equal to 101% of the principal amount of the notes repurchased, plus accrued and unpaid interest, upon the occurrence of specific kinds of changes of control.
The holders of the 2031 Notes have the right to require us to repurchase all or a portion of the 2031 Notes at a purchase price equal to 101% of the principal amount of the notes repurchased, plus accrued and unpaid interest, upon the occurrence of a change of control.
The Credit Facility is secured by substantially all assets of the borrowing parties, including (i) pledges of 100% of the stock or other equity interest of each domestic subsidiary that is directly owned by such entity and (ii) 65% of the stock or other equity interest of each foreign subsidiary that is directly owned by such entity, in each case subject to customary exceptions.
The Credit Facility is secured by substantially all of our assets and the assets of our subsidiaries guaranteeing the Credit Facility, including (i) pledges of 100% of the stock or other equity interest of each domestic subsidiary that is directly owned by such entity and (ii) 65% of the stock or other equity interest of each foreign subsidiary that is directly owned by such entity, in each case subject to customary exceptions.
Stock Repurchases During fiscal 2024, we repurchased approximately 0.3 million shares of our non-voting common stock (CENTA) on the open market at an aggregate cost of approximately $10.7 million and approximately 3 thousand shares of our voting common stock (CENT) on the open market at an aggregate cost of approximately $109 thousand.
During fiscal 2024, we repurchased approximately 0.3 million shares of our non-voting common stock (CENTA) and approximately 3 thousand shares of our voting common stock (CENT) on the open market at an aggregate cost of approximately $10.8 million.
We expect that our principal sources of funds will be cash generated from our operations, proceeds from our debt and equity offerings, and, if necessary, borrowings under our $750 million asset backed loan facility. See Note 11 - Long-Term Debt , for more information about our debt.
We expect that our principal sources of funds will be cash generated from our operations, proceeds from our debt and equity offerings, and, if necessary, borrowings under our $600 million asset backed loan facility. See Note11 - Long-Term Debt , for more information about our debt.
Debt repayments do not reflect the unamortized portion of deferred financing costs associated with the 2028 Notes, 2030 Notes and 2031 Notes of approximately $10.3 million as of September 28, 2024, of which $1.6 million is amortizable until February 2028, $4.8 million is amortizable until October 2030 and $4.0 million is amortizable until April 2031, and is included in the carrying value of the long-term debt.
Debt repayments do not reflect the unamortized portion of deferred financing costs associated with the 2028 Notes, 2030 Notes and 2031 Notes of approximately $8.5 million as of September 27, 2025, of which $1.1 million is amortizable until February 2028, $4.0 million is amortizable until October 2030 and $3.4 million is amortizable until April 2031, and is included in the carrying value of the long-term debt.
In fiscal 2024, our consolidated net sales were $3.2 billion, of which our Pet segment, or Pet, accounted for approximately $1.8 billion and our Garden segment, or Garden, accounted for approximately $1.4 billion.
In fiscal 2025, our consolidated net sales were $3.1 billion, of which our Pet segment, or Pet, accounted for approximately $1.8 billion and our Garden segment, or Garden, accounted for approximately $1.3 billion.
We may redeem some or all of the 2028 Notes, at our option, at any time before December 31, 2024 for 101.708%, on or after January 1, 2025 for 100.854% and on or after January 1, 2026 for 100.0%, plus accrued and unpaid interest.
We may redeem some or all of the 2028 Notes at our option, through December 31, 2025 for 101.854% and on or after January 1, 2026 for 100.0%, plus accrued and unpaid interest.
We completed our qualitative assessment of potential goodwill impairment and determined that it was more likely than not the fair values of our reporting segments were greater than their carrying amount in fiscal year 2024, and accordingly, no further testing of goodwill was required in fiscal 2024. 31 In connection with our annual goodwill impairment testing performed during fiscal 2023, we elected to bypass the qualitative assessment and proceeded directly to performing the quantitative goodwill impairment test.
In connection with our annual goodwill impairment testing performed during fiscal 2023, we elected to bypass the qualitative assessment and proceeded directly to performing the quantitative goodwill impairment test. We completed our quantitative assessment of potential goodwill and determined that it was more likely than not the fair values of our reporting segments were greater than their carrying amounts.
Our expected revenues were based on our future operating plan and market growth or decline estimates for future years. We recognized impairment losses on certain intangible assets of $12.8 million and $11.5 million in fiscal years 2024 and 2023, respectively, and there were no impairment losses recorded in fiscal year 2022.
Our expected revenues were based on our future operating plan and market growth or decline estimates for future years. We recognized impairment losses on certain intangible assets of $1.0 million, $12.8 million and $11.5 million in fiscal 2025, 2024 and 2023, respectively.
The 2028 Notes contain customary high-yield covenants, including covenants limiting debt incurrence and restricted payments, subject to certain baskets and exceptions. We were in compliance with all financial covenants as of September 28, 2024. Asset-Based Loan Facility On December 16, 2021, we entered into a Third Amended and Restated Credit Agreement (“Credit Agreement”).
The 2028 Notes contain customary high-yield covenants, including covenants limiting debt incurrence and restricted payments, subject to certain baskets and exceptions. We were in compliance with all financial covenants as of September 27, 2025. Asset-Based Loan Facility On November 7, 2025, we entered into a Fourth Amended and Restated Credit Agreement (the “Credit Agreement”).
Gain from litigation and investment impairment (8) Within corporate, the Company received $3.2 million during the fourth quarter of fiscal 2024 in settlement of litigation which gain is included in selling, general and administrative expense.
Gain from litigation and investment impairment (6) In fiscal 2024, within corporate, we received $3.2 million in settlement of litigation, the gain of which is included in selling, general and administrative expense.
The Credit Agreement provides for a $750 million principal amount senior secured asset-based revolving credit facility, with up to an additional $400 million principal amount available with the consent of the Lenders, as defined, if we exercise the uncommitted accordion feature set forth therein (collectively, the “Credit Facility”). The Credit Facility matures on December 16, 2026.
The Credit Agreement provides for a $600 million principal amount senior secured asset-based revolving credit facility, with up to an additional $400 million principal amount available, as defined, if we exercise the uncommitted accordion feature set forth therein (collectively, the “Credit Facility”). The Credit Facility matures on November 7, 2030.
Other income (expense) was an expense of $5.1 million in fiscal 2024 compared to income of $1.5 million in fiscal 2023, due primarily to a $7.5 million impairment in fiscal 2024 for two private company investments. Income Tax Our effective income tax rate was 23.2% for fiscal 2024 compared to 22.4% for fiscal 2023.
Other income (expense) was an expense of $0.5 million in fiscal 2025 compared to $5.1 million in fiscal 2024. The decrease in expense was due primarily to a $7.5 million non-cash impairment in fiscal 2024 for two private company investments. Income Tax Our effective income tax rate was 24.4% for fiscal 2025 compared to 23.2% for fiscal 2024.
As of September 28, 2024, we had $82 million remaining under our 2019 Repurchase Authorization. In February 2019, the Board of Directors authorized us to make supplemental purchases to minimize dilution resulting from issuances under our equity compensation plans (the "Equity Dilution Authorization").
As of September 27, 2025, the Company had $46.5 million remaining under its 2024 Repurchase Authorization. In February 2019, the Board of Directors authorized us to make supplemental purchases to minimize dilution resulting from issuances under our equity compensation plans (the "Equity Dilution Authorization").
On a non-GAAP basis, Pet operating income increased $7.3 million in fiscal 2024 as compared to fiscal 2023 and operating margin improved to 12.2% in fiscal 2024 from 11.5% in fiscal 2023.
On a non-GAAP basis, Pet operating income increased $1.9 million in fiscal 2025 as compared to fiscal 2024 and operating margin improved to 12.5% in fiscal 2025 from 12.2% in fiscal 2024.
On a non-GAAP basis, net income in fiscal 2024 was $142.4 million, or $2.13 per diluted share, compared to $138.5 million, or $2.07 per diluted share, for fiscal 2023.
On a non-GAAP basis, net income in fiscal 2025 was $174.2 million, or $2.73 per diluted share, compared to $142.4 million, or $2.13 per diluted share, for fiscal 2024.
The Credit Facility is subject to a borrowing base that is calculated using a formula based upon eligible receivables and inventory, and at our election, eligible real property, minus certain reserves. Proceeds of the Credit Facility may be used for general corporate purposes. Net availability under the Credit Facility was approximately $481 million as of September 28, 2024.
The Credit Facility is subject to a borrowing base that is calculated using a formula based upon eligible receivables and inventory, and at our election, eligible real property, minus certain reserves. Proceeds of the Credit Facility may be used for general corporate purposes.
As of November 21, 2024, we had $30.3 million remaining under our 2019 Repurchase Authorization. 18 Results of Operations (GAAP) The following table sets forth, for the periods indicated, the relative percentages that certain income and expense items bear to net sales: Fiscal Year Ended September 28, 2024 September 30, 2023 September 24, 2022 Net sales 100.0 % 100.0 % 100.0 % Cost of goods sold and occupancy 70.5 71.4 70.3 Gross profit 29.5 28.6 29.7 Selling, general and administrative 23.7 22.2 21.9 Operating income 5.8 6.4 7.8 Interest expense, net (1.2) (1.5) (1.7) Other expense, net (0.2) — (0.1) Income taxes 1.0 1.1 1.4 Net income 3.4 % 3.8 % 4.6 % Fiscal 2024 Compared to Fiscal 2023 Net Sales Net sales for fiscal 2024 decreased $109.6 million, or 3.3%, to $3,200.5 million from $3,310.1 million in fiscal 2023.
Results of Operations (GAAP) The following table sets forth, for the periods indicated, the relative percentages that certain income and expense items bear to net sales: Fiscal Year Ended September 27, 2025 September 28, 2024 September 30, 2023 Net sales 100.0 % 100.0 % 100.0 % Cost of goods sold and occupancy 68.1 70.5 71.4 Gross profit 31.9 29.5 28.6 Selling, general and administrative 23.9 23.7 22.2 Operating income 8.0 5.8 6.4 Interest expense, net (1.0) (1.2) (1.5) Other expense, net — (0.2) — Income taxes 1.7 1.0 1.1 Net income 5.2 % 3.4 % 3.8 % Fiscal 2025 Compared to Fiscal 2024 Net Sales Net sales for fiscal 2025 decreased $71.4 million, or 2.2%, to $3,129.1 million from $3,200.5 million in fiscal 2024.
Base Rate is defined as the highest of (a) the Truist prime rate, (b) the Federal Funds Rate plus 0.50%, (c) one-month SOFR plus 1.00% and (d) 0.00%.
Base Rate is defined as the highest of (a) the Truist prime rate, (b) the Federal Funds Rate plus 0.50%, (c) one-month SOFR plus 1.00% and (d) 0.00%. The applicable margin for SOFR-based borrowings fluctuates between1.00%-1.50% and the applicable margin for Base Rate borrowings fluctuates between 0.00%-0.50%.
Pet operating income increased $5.4 million, or 2.7%, to $203.4 million in fiscal 2024 from $198.0 million in fiscal 2023, due to an improved gross margin partially offset by lower net sales and increased selling, general and administrative expenses. Pet operating margin increased from 10.5% in fiscal 2023 to 11.1% in fiscal 2024.
Pet operating income increased $12.3 million, or 6.0%, to $215.7 million in fiscal 2025 from $203.4 million in fiscal 2024, due to an improved gross margin and decreased selling, general and administrative expenses partially offset by lower net sales. Pet operating margin increased from 11.1% in fiscal 2024 to 12.0% in fiscal 2025.
To encourage retailers and distributors to stock large quantities of inventory, industry practice has been for manufacturers to give extended credit terms and/or promotional discounts. Operating Activities Net cash provided by operating activities increased $13.3 million, from $381.6 million in fiscal 2023 to $394.9 million in fiscal 2024.
To encourage retailers and distributors to stock large quantities of inventory, industry practice has been for manufacturers to give extended credit terms and/or promotional discounts. Operating Activities Net cash provided by operating activities decreased $62.4 million, from $394.9 million in fiscal 2024 to $332.5 million in fiscal 2025.
Generally, during the first fiscal quarter, accounts receivable reach their lowest level while inventory, accounts payable and short-term borrowings begin to increase. During the second fiscal quarter, receivables, accounts payable and short-term borrowings increase, reflecting the build-up of inventory and related payables in anticipation of the peak lawn and garden selling season.
During the second fiscal quarter, accounts receivable, accounts payable and short-term borrowings increase, reflecting the build-up of inventory and related payables in anticipation of the peak lawn and garden selling season.
In August 2019, our Board of Directors authorized a share repurchase program to purchase up to $100 million of our common stock (the "2019 Repurchase Authorization"). The 2019 Repurchase Authorization has no fixed expiration date and expires when the amount authorized has been used or the Board withdraws its authorization.
In December 2024, our Board of Directors authorized a $100 million increase in the share repurchase program (the "2024 Repurchase Authorization"). The 2024 Repurchase Authorization has no fixed expiration date and expires when the amount authorized has been used or 25 the Board withdraws its authorization.
Selling, General and Administrative Selling, general and administrative expenses increased $22.1 million, or 3.0%, from $736.2 million in fiscal 2023 to $758.3 million in fiscal 2024. As a percentage of net sales, selling, general and administrative expenses increased from 22.2% in fiscal 2023 to 23.7% in fiscal 2024.
Selling, General and Administrative Selling, general and administrative expenses decreased $11.0 million, or 1.5%, from $758.3 million in fiscal 2024 to $747.3 million in fiscal 2025. As a percentage of net sales, selling, general and administrative expenses increased from 23.7% in fiscal 2024 to 23.9% in fiscal 2025.
The following table indicates each class of similar products which represented approximately 10% or more of our consolidated net sales in the fiscal years presented: Category 2024 2023 2022 (in millions) Other garden products $ 802.6 $ 832.2 $ 865.3 Other pet products 701.4 699.4 765.9 Other manufacturers' products 735.9 734.9 730.2 Dog & cat products 534.2 568.6 542.9 Wild bird 426.4 475.0 434.3 Total $ 3,200.5 $ 3,310.1 $ 3,338.6 Pet net sales decreased $44.4 million, or 2.4%, to $1,832.8 million in fiscal 2024 from $1,877.2 million in fiscal 2023.
The following table indicates each class of similar products which represented approximately 10% or more of our consolidated net sales in the fiscal years presented: Category 2025 2024 2023 (in millions) Other garden products $ 808.2 $ 832.9 $ 832.2 Other pet products 602.6 635.0 699.4 Other manufacturers' products 664.7 705.6 734.9 Dog & cat products 592.8 600.6 568.6 Wild bird 460.8 426.4 475.0 Total $ 3,129.1 $ 3,200.5 $ 3,310.1 Pet net sales decreased $30.8 million, or 1.7%, to $1,802.0 million in fiscal 2025 from $1,832.8 million in fiscal 2024.
We were in compliance with all financial covenants under the Credit Facility as of September 28, 2024. Summarized Financial Information for Guarantors and the Issuer of Guaranteed Securities Central (the "Parent/Issuer") issued $400 million of 2031 Notes in April 2021, $500 million of 2030 Notes in October 2020, and $300 million of 2028 Notes in December 2017.
Summarized Financial Information for Guarantors and the Issuer of Guaranteed Securities Central (the "Parent/Issuer") issued $400 million of 2031 Notes in April 2021, $500 million of 2030 Notes in October 2020, and $300 million of 2028 Notes in December 2017.
Net Income and Earnings Per Share Our net income for fiscal 2024 was $108.0 million, or $1.62 per diluted share, compared to $125.6 million, or $1.88 per diluted share, for fiscal 2023.
Net Income and Earnings Per Share Our net income for fiscal 2025 was $162.8 million, or $2.55 per diluted share, compared to $108.0 million, or $1.62 per diluted share, for fiscal 2024.
We incurred approximately $4.8 million of debt issuance costs in conjunction with this transaction, which included underwriter fees and legal, accounting and rating agency expenses. The debt issuance costs are being amortized over the term of the 2028 Notes. The 2028 Notes require semiannual interest payments on February 1 and August 1.
We incurred approximately $6 million of debt issuance costs in conjunction with this issuance, which included underwriter fees and legal, accounting and rating agency expenses. The debt issuance costs are being amortized over the term of the 2031 Notes. The 2031 Notes require semi-annual interest payments on April 30 and October 30.
The Credit Facility includes a $50 million sublimit for the issuance of commercial and standby letters of credit and a $75 million sublimit for Swing Loan borrowings. As of September 28, 2024, there were no borrowings outstanding and no letters of credit outstanding under the Credit Facility.
The Credit Facility includes a $50 million sublimit for the issuance of standby and commercial letters of credit and a $75 million sublimit for swing loan borrowings.
During fiscal 2023, we repurchased approximately 0.8 million shares of our non-voting common stock (CENTA) on the open market at an aggregate cost of approximately $22.9 million and approximately 0.3 million shares of our voting common stock (CENT) on the open market at an aggregate cost of approximately $8.7 million.
Stock Repurchases During fiscal 2025, we repurchased approximately 3.2 million shares of our non-voting common stock (CENTA) and approximately 1.4 million shares of our voting common stock (CENT) on the open market at an aggregate cost of approximately $148.4 million.
From time to time in the future, there may be other items that we may exclude if we believe that doing so is consistent with the goal of providing useful information to investors and management.
The tax impact of the non-GAAP adjustments is calculated based on the consolidated effective tax rate on a GAAP basis, applied to the non-GAAP adjustments. From time to time in the future, there may be other items that we may exclude if we believe that doing so is consistent with the goal of providing useful information to investors and management.
Sales of branded products represented approximately 78% of our net sales in both fiscal 2024 and fiscal 2023, and sales of other manufacturers' products represented 22% of our net sales.
In fiscal 2025, sales of branded products represented approximately 79% of our net sales, compared to 78% in fiscal 2024, and sales of other manufacturers' products represented 21% of our net sales.
In fiscal 2024, our operating income was $185 million, consisting of income from our Pet segment of $203 million, income from our Garden segment of $82 million and corporate expenses of $100 million. Fiscal 2024 Financial Highlights Financial summary: • Net sales for fiscal 2024 decreased $109.6 million, or 3.3%, to $3.2 billion.
In fiscal 2025, our operating income was $250 million, consisting of income from our Pet segment of $216 million, income from our Garden segment of $142 million and corporate expenses of $108 million. Fiscal 2025 Financial Highlights Financial summary: • Net sales for fiscal 2025 decreased $71.4 million, or 2.2%, to $3.1 billion.
(2) During the third quarter of fiscal 2024, we recognized incremental expense of $11.1 million in the consolidated statement of operations, from the decision to exit the pottery business, the closure of a live goods distribution facility in Delaware and the relocation of our grass seed research facility.
(3) During fiscal 2024, we recognized incremental expense of $20.3 million in our Garden segment in the consolidated statement of operations, from the closure of a manufacturing facility in California, the consolidation of our Southeast distribution network, the decision to exit the pottery business, the closure of a live goods distribution facility in Delaware, the relocation of our grass seed research facility related, and facility closures announced in fiscal 2023.
During the period September 29, 2024 through November 21, 2024, we repurchased 1.3 million shares of our non-voting common stock (CENTA) and 0.4 million shares of our voting common stock (CENT) on the open market at an aggregate cost of $51.7 million. As of November 21, 2024, we had $30.3 million remaining on under our 2019 Repurchase Authorization.
Fiscal 2025 Stock Repurchases During fiscal 2025, we repurchased 3.2 million shares of our non-voting common stock (CENTA) and 1.4 million shares of our voting common stock (CENT) on the open market at an aggregate cost of $148.4 million. As of September 27, 2025, we had $46.5 million remaining under our 2024 Repurchase Authorization.
We completed our quantitative assessment of potential goodwill and determined that it was more likely than not the fair values of our reporting segments were greater than their carrying amounts.
We completed our qualitative assessment of potential goodwill impairment and determined that it was more likely than not the fair values of our reporting segments were greater than their carrying amount in fiscal year 2024, and accordingly, no further testing of goodwill was required in fiscal year 2024.
The non-GAAP adjustments made reflect the following: Facility closures and business exits (1) During the fourth quarter of fiscal year 2024, we recognized incremental expense of $7.5 million in our Pet segment in the consolidated statement of operations, from the closure of manufacturing facilities in California and Arizona.
(4) During fiscal 2024, we recognized incremental expense of $7.5 million in our Pet segment in the consolidated statement of operations, from the closure of manufacturing facilities in California and Arizona.
In presenting the summarized financial statements, the equity method of accounting has been applied to the Parent/Issuer's interests in the Guarantor Subsidiaries.
In presenting the summarized financial statements, the equity method of accounting has been applied to the Parent/Issuer's interests in the Guarantor Subsidiaries. The summarized information excludes financial information of the Non-Guarantors, including earnings from and investments in these entities.
On a non-GAAP basis, operating income declined $4.4 million in fiscal 2024. • Net income for fiscal 2024 was $108.0 million, or $1.62 per share on a diluted basis compared to $125.6 million, or $1.88 per share on a diluted basis in fiscal 2023.
On a non-GAAP basis, operating income increased $42.2 million, or 19.0%, in fiscal 2025. • Net income for fiscal 2025 was $162.8 million, or $2.55 per share on a diluted basis compared to $108.0 million, or $1.62 per share on a diluted basis in fiscal 2024.
Liquidity and Capital Resources We have financed our growth through a combination of internally generated funds, bank borrowings, supplier credit, and sales of equity and debt securities to the public. Our business is seasonal and our working capital requirements and capital resources track closely to this seasonal pattern.
Substantially all of the Garden segment’s operating income is typically generated in this period. 24 Liquidity and Capital Resources We have financed our growth through a combination of internally generated funds, bank borrowings, supplier credit, and sales of equity and debt securities to the public.
The 2031 Notes were issued in a private placement under Rule 144A and will not be registered under the Securities Act of 1933. We may redeem some or all of the 2031 Notes at any time, at our option, prior to April 30, 2026, at the principal amount plus a "make whole" premium.
We may redeem some or all of the 2031 Notes at any time, at our option, prior to April 30, 2026, at the principal amount plus a "make whole" premium.
The debt issuance costs are being amortized over the term of the Credit Facility. The Credit Facility continues to contain customary covenants, including financial covenants which require us to maintain a minimum fixed charge coverage ratio of 1:1 upon triggered quarterly testing (e.g. when availability falls below certain thresholds established in the agreement), reporting requirements and events of default.
The Credit Facility contains customary covenants, including a financial covenant which requires us to maintain a minimum fixed charge coverage ratio of 1:1 when availability falls below certain thresholds established in the Credit Agreement, reporting requirements and events of default.
We were in compliance with all financial covenants as of September 28, 2024. $300 Million 5.125% Senior Notes due 2028 In December 2017, we issued $300 million aggregate principal amount of 5.125% senior notes due February 2028 (the "2028 Notes"). We used the net proceeds from the offering to finance acquisitions and for general corporate purposes.
We were in compliance with all financial covenants as of September 27, 2025. $300 Million 5.125% Senior Notes due 2028 In December 2017, we issued $300 million aggregate principal amount of 5.125% senior notes due February 2028 (the "2028 Notes").
On a non-GAAP basis, net income in fiscal 2024 was $142.4 million, or $2.13 per share on a diluted basis compared to $138.5 million, or $2.07 per share on a diluted basis in fiscal 2023.
On a non-GAAP basis, net income in fiscal 2025 was $174.2 million, or $2.73 per share on a diluted basis compared to $142.4 million, or $2.13 per share on a diluted basis in fiscal 2024. Recent Developments: Wind-down of U.K.
Organic net sales decreased 3.9% with Pet organic sales decreasing 5.9% and Garden organic sales decreasing 1.2%. • Gross profit for fiscal 2024 declined $3.1 million, or 0.3%, to $943.7 million while gross margin increased 90 basis points in fiscal 2024 to 29.5%, from 28.6% in fiscal 2023.
Pet net sales decreased $30.8 million, or 1.7%, and Garden net sales decreased $40.6 million, or 3.0%. • Gross profit for fiscal 2025 increased $53.6 million, or 5.7%, to $997.3 million and gross margin increased 240 basis points in fiscal 2025 to 31.9%, from 29.5% in fiscal 2024.
However, we cannot assure you that these sources will continue to provide us with sufficient liquidity and, should we require it, that we will be able to obtain financing on terms satisfactory to us, or at all. 26 We anticipate that our capital expenditures, which are related primarily to replacements and expansion of and upgrades to plant and equipment and also investment in our continued implementation of a scalable enterprise-wide information technology platform, will be approximately $70 million over the next 12 months.
We anticipate that our capital expenditures, which are related primarily to replacements and expansion of and upgrades to plant and equipment and also investment in our continued implementation of a scalable enterprise-wide information technology platform, will be approximately $50 to 60 million over the next 12 months.
Fiscal 2024 included 52 weeks while fiscal 2023 included 53 weeks. Our branded product sales, which include products we produce under Central brand names and products we produce under third-party brands, decreased $80.2 million, and sales of other manufacturers’ products decreased $29.4 million.
Our branded product sales, which include products we produce under Central brand names and products we produce under third-party brands, decreased $30.6 million, and sales of other manufacturers’ products decreased $40.8 million.
We used a portion of the net proceeds from the offering to repay all outstanding borrowings under our Amended Credit Facility, with the remainder used for general corporate purposes. We incurred approximately $6 million of debt issuance costs in conjunction with this issuance, which included underwriter fees and legal, accounting and rating agency expenses.
We used the net proceeds from the offering to finance acquisitions and for general corporate purposes. 26 We incurred approximately $4.8 million of debt issuance costs in conjunction with this transaction, which included underwriter fees and legal, accounting and rating agency expenses. The debt issuance costs are being amortized over the term of the 2028 Notes.
The increase in cash provided was due primarily to changes in our working capital accounts, due to increases in accounts payable and accrued expenses, partially offset by a lower amount of cash generated from the decrease in accounts receivable, as compared to the prior year.
The decrease in cash provided was due primarily to changes in our working capital accounts, due to decreases in inventory and accrued expenses, partially offset by cash provided by the long-term obligations in the current year as compared to cash used for other long-term obligations in the prior year.
The summarized information excludes financial information of the Non-Guarantors, including earnings from and investments in these entities. 29 Summarized Statements of Operations (in thousands) Fiscal Year Ended Fiscal Year Ended September 28, 2024 September 30, 2023 (in thousands) Parent/Issuer Guarantors Parent/Issuer Guarantors Net sales $ 694,083 $ 2,491,748 $ 768,207 $ 2,531,503 Gross profit 154,310 771,737 166,370 767,480 Income (loss) from operations (6,164) 189,406 (32,001) 244,164 Equity in earnings of Guarantor subsidiaries 163,797 — 191,793 — Net income (loss) (58,047) 163,797 (63,840) 191,793 Summarized Balance Sheet Information (in thousands) As of As of September 28, 2024 September 30, 2023 (in thousands) Parent/Issuer Guarantors Parent/Issuer Guarantors Current assets $ 936,497 $ 896,476 $ 661,660 $ 999,218 Intercompany receivable from Non-guarantor subsidiaries 76,084 — 69,404 — Other assets 3,799,521 3,330,344 3,402,000 2,762,797 Total assets $ 4,812,102 $ 4,226,820 $ 4,133,064 $ 3,762,015 Current liabilities $ 164,607 $ 342,289 $ 155,793 $ 294,686 Intercompany payable from Non-guarantor subsidiaries — 1,003 — 766 Long-term debt 1,189,655 154 1,187,771 186 Other liabilities 1,888,312 234,308 1,308,736 60,611 Total liabilities $ 3,242,574 $ 577,754 $ 2,652,300 $ 356,249 Contractual Obligations The table below presents our significant contractual cash obligations by fiscal year: Contractual Obligations Fiscal 2025 Fiscal 2026 Fiscal 2027 Fiscal 2028 Fiscal 2029 Thereafter Total (in millions) Long-term debt, including current maturities (1) $ 0.2 $ 0.1 $ 0.1 $ 0.1 $ — $ 1,200.0 $ 1,200.5 Interest payment obligations (2) 52.5 52.5 52.5 44.8 37.1 43.3 282.7 Operating leases 65.0 53.7 42.6 30.8 24.7 55.6 272.4 Purchase commitments (3) 102.1 14.5 8.5 6.0 2.1 2.4 135.6 Performance-based payments (4) — — — — — — — Total $ 219.8 $ 120.8 $ 103.7 $ 81.7 $ 63.9 $ 1,301.3 $ 1,891.2 (1) Excludes $3.0 million of outstanding letters of credit related to normal business transactions.
Summarized Statements of Operations Fiscal Year Ended September 27, 2025 September 28, 2024 Parent/Issuer Guarantors Parent/Issuer Guarantors (in thousands) Net sales $ 770,812 $ 2,348,267 $ 694,083 $ 2,491,748 Gross profit 181,997 808,803 154,310 771,737 Income (loss) from operations (5,724) 267,249 (6,164) 189,406 Equity in earnings of Guarantor subsidiaries 223,637 — 163,797 — Net income (loss) (45,373) 223,637 (58,047) 163,797 Summarized Balance Sheet Information As of As of September 27, 2025 September 28, 2024 Parent/Issuer Guarantors Parent/Issuer Guarantors (in thousands) Current assets $ 1,065,394 $ 881,526 $ 936,497 $ 896,476 Intercompany receivable from Non-guarantor subsidiaries 71,716 — 76,084 — Other assets 4,066,291 3,580,246 3,799,521 3,330,344 Total assets $ 5,203,401 $ 4,461,772 $ 4,812,102 $ 4,226,820 Current liabilities $ 165,447 $ 362,348 $ 164,607 $ 342,289 Intercompany payable from Non-guarantor subsidiaries — 1,250 — 1,003 Long-term debt 1,191,541 100 1,189,655 154 Other liabilities 2,235,827 217,213 1,888,312 234,308 Total liabilities $ 3,592,815 $ 580,911 $ 3,242,574 $ 577,754 28 Contractual Obligations The table below presents our significant contractual cash obligations by fiscal year: Contractual Obligations Fiscal 2026 Fiscal 2027 Fiscal 2028 Fiscal 2029 Fiscal 2030 Thereafter Total (in millions) Long-term debt, including current maturities (1) $ 0.1 $ 0.1 $ — $ — $ — $ 1,200.0 $ 1,200.2 Interest payment obligations (2) 52.5 52.5 44.8 37.1 26.8 16.5 230.2 Operating leases 67.2 56.1 44.3 37.9 32.5 56.7 294.7 Purchase commitments (3) 85.0 10.2 7.6 3.8 1.5 — 108.1 Performance-based payments (4) — — — — — — — Total $ 204.8 $ 118.9 $ 96.7 $ 78.8 $ 60.8 $ 1,273.2 $ 1,833.2 (1) Excludes $3.0 million of outstanding letters of credit related to normal business transactions.
On a non-GAAP basis, gross margin increased 110 basis points in fiscal 2024. • Our operating income declined $25.3 million, or 12.0%, to $185.4 million in fiscal 2024.
On a non-GAAP basis, gross margin increased 210 basis points in fiscal 2025. • Our operating income increased $64.7 million, or 34.9%, to $250.0 million in fiscal 2025.
The decrease in Garden was due primarily to an approximately $19 million write-down of the value of our grass seed inventory due to a recent significant decrease in the market prices of grass seed and what we believe to be an industry-wide over supply of grass seed and lower sell through in our Live Goods business.
The increase in gross profit and gross margin in Garden was due primarily to improvements in our Live Goods business in fiscal 2025, from cost reduction initiatives under our Cost and Simplicity agenda and the adverse impact in fiscal 2024 from the write-down of the value of our grass seed inventory in fiscal 2024 of approximately $20 million, due to a significant decrease in the market prices of grass seed and an industry-wide over supply of grass seed.
The increase in cash used in investing activities was due primarily to our acquisition of TDBBS, LLC. Net cash used in investing activities decreased $108.4 million from $143.0 million in fiscal 2022 to $34.6 million in fiscal 2023.
Investing Activities Net cash used in investing activities decreased $60.3 million from $105.2 million in fiscal 2024 to $44.9 million in fiscal 2025. The decrease in cash used in investing activities was due primarily to our acquisition of TDBBS, LLC in fiscal 2024.
The decrease in net interest expense was due to increased interest income due primarily to higher cash balances during fiscal 2024. Debt outstanding on September 28, 2024 was $1,190.0 million compared to $1,188.2 million as of September 30, 2023. Our average borrowing rate was 4.5% in both fiscal 2024 and fiscal 2023.
Net Interest Expense Net interest expense decreased $5.1 million, or 13.4%, from $37.9 million in fiscal 2024 to $32.8 million in fiscal 2025. The decrease in net interest expense was due to increased interest income resulting from higher cash balances during fiscal 2025. Debt outstanding on September 27, 2025 and September 28, 2024 was $1.2 billion.
The decrease in cash used in financing activities during the current year was due primarily to lower stock repurchase activity in fiscal 2024 compared to fiscal 2023. Net cash used in financing activities decreased $29.2 million from $66.8 million of cash used in fiscal 2022 to $37.6 million of cash used in fiscal 2023.
Financing Activities Net cash used in financing activities increased $131.2 million from $25.4 million in fiscal 2024 to $156.6 million in fiscal 2025. The increase in cash used in financing activities during the current year was due primarily to higher stock repurchases in fiscal 2025 compared to fiscal 2024.
Both segments were adversely impacted by fiscal 2024 facility closure projects under our Cost and Simplicity initiative. On a non-GAAP basis, excluding the charges associated with the facility closures in fiscal 2024, gross profit increased $3.5 million and gross margin improved 110 basis points to 30.0% in fiscal 2024.
On a non-GAAP basis, excluding approximately $6 million in charges associated with the facility closures in fiscal 2025 and approximately $16 million in fiscal 2024, gross profit increased $42.8 million and gross margin improved 210 basis points to 32.1% in fiscal 2025 from 30.0% in fiscal 2024.
These declines were partially offset by increased sales in our animal health business. Pet branded sales decreased $45.4 million, and sales of other manufacturers' products increased $1.0 million. Garden net sales decreased $65.2 million, or 4.5%, to $1,367.7 million in fiscal 2024 from $1,432.9 million in fiscal 2023.
The decline in Pet net sales was due primarily to lower sales of durable items impacting our outdoor cushions, pet beds and aquatics businesses. These declines were partially offset by increased sales in our animal health business. Pet branded sales decreased $36.0 million, and sales of other manufacturers' products increased $5.2 million.